Abstract | Autophagy, or 'self-eating', is an adaptive process that enables cells to cope with metabolic, toxic, and even infectious stressors. Although the adaptive capability of autophagy is generally considered beneficial, autophagy can also enhance nutrient utilization and improve growth characteristics of cancer cells. Moreover, autophagy can promote greater cellular robustness in the context of therapeutic intervention. In advanced prostate cancer, preclinical data provide evidence that autophagy facilitates both disease progression and therapeutic resistance. Notably, androgen deprivation therapy, taxane-based chemotherapy, targeted kinase inhibition, and nutrient restriction all induce significant cellular distress and, subsequently, autophagy. Understanding the context-dependent role of autophagy in cancer development and treatment resistance has the potential to improve current treatment of advanced prostate cancer. Indeed, preclinical studies have shown that the pharmacological inhibition of autophagy (with agents including chloroquine, hydroxychloroquine, metformin, and desmethylclomipramine) can enhance the cell-killing effect of cancer therapeutics, and a number of these agents are currently under investigation in clinical trials. However, many of these autophagy modulators are relatively nonspecific, and cytotoxicity in noncancerous tissues is still a concern. Moving forward, refinement of autophagy modulation is needed.
Introduction
In good health and in disease, the biomolecular adaptions to 'stress' are necessarily dynamic. Complex, integrated biological processes, such as inflammation, immune response, and nutrient depletion require c oordinated regu lation of cellular machinery and efficient use of available nutrients. Autophagy, or 'self-eating' is an essential and highly conserved homeostatic process that can achieve such coordinated regulation. Although 'selfeating' has negative connotations, research shows that a basal level of autophagy is critical for normal development and homeostasis. [1] [2] [3] Autophagy maintains cellular homeo stasis by metabolizing cytoplasmic protein waste through the lysosomal system. Furthermore, research has shown that autophagy can suppress tumour development. 4, 5 However, autophagy is multifaceted, and not always protective. In established tumours, autophagy can meet the heightened nutrient demand of proliferative cancer cells, 5 and can enable cancer cell survival during therapeutic intervention by radiotherapy, chemotherapy, and hormone therapy. 6 Understanding the contextdependent role of autophagy in cancer development, and specifically in treatment resistance, has the potential to improve current treatment paradigms, including treatment of advanced prostate cancer. [7] [8] [9] Current treatments for prostate cancer have limited and transient effectiveness. The adaptive capabilities of autophagy potentially contribute to this limited effectiveness, and the use of autophagy manipulation concurrently with prostate cancer therapy is under investigation. In this Review, we provide an overview of autophagy and the available data in support of autophagic modulation (with added emphasis on alterations occurring within prostate cancer models). We describe current prostate cancer treatments associated with alterations in autophagy, and the current status of research providing support for the use of adjuvant autophagic modulation alongside current prostate cancer treatments.
Autophagy and tumorigenesis
Autophagy Autophagy (also known as macroautophagy) is a highly conserved evolutionary process that is involved in a number of cellular homeostatic processes that regulate cytoplasmic biomass, organellar abundance, and organellar distribution, and that remove harmful protein aggregates and intracellular toxins. 2, 10, 11 Autophagy also has important immunological roles, and is capable of removing intracellular pathogens and influencing both innate and adaptive immunity. [11] [12] [13] [14] The exact morphological and molecular steps of autophagy have been extensively reviewed, 15 and can be briefly summarized in two essential steps (Figure 1 ). During autophagy, cytoplasmic material is engulfed by an isolation membrane called a phagophore, producing a double-membrane structure known as an autophagosome. 15 Autophagosomes are then trafficked to lysosomes, where the contents are destroyed by lysosomal enzymes. 15 The active cycling of cytoplasmic material through the lysosomal system, or autophagic flux, is an essential d eterminant of autophagic activity in research models. 16 Perhaps not surprisingly, given the diverse metabolic and immunological functions of autophagy, autophagic dysregulation has been linked to tumorigenesis. Mice that are heterozygous for disruption of the autophagy gene Becn1 develop multiple spontaneous malignancies. 17 Furthermore, the monoallelic deletion of the human homologue of this gene occurs in several human cancers. 2 Autophagy is upregulated at the immunological synapse between dendritic cells and CD4+ T cells, influencing T-cell activation and possibly antitumour immunity. The autophagy system is capable of tremendous plasticity, and determination of the consequences of too little or too much autophagy on immune system function requires further research. 11, 12 Nevertheless, although a protective role for autophagy is generally accepted, in established tumours autophagy might actually facilitate carcinogenesis. 18, 19 Studies have shown autophagy to be upregulated in the internal environment of tumours, areas that are characteristically low in nutrient and oxygen levels. 4, 5, 20 Experimental models with knockout of essential autophagy genes (Becn1, Atg5, and Atg7) are sensitive to metabolic stress. 18 Moreover, the upregulation of key autophagy markers in tumour tissues has been linked to poor therapeutic outcomes. 9 The apparently context-dependent role of auto phagy, as defined by the presence or absence of disease, is complicated by the cross-talk between the autophagic and apoptotic molecular pathways. 2, 21, 22 Interactions have been identified between intermediates from both pathways, such as the apoptosis regulator Bcl-2 and the autophagic Beclin 1, and the autophagic LC3B ( microtubule-associated proteins 1A/1B light chain 3B) and the apoptotic tumour necrosis factor receptor superfamily member 6 (also known as fas), and these interactions are largely counter-regulatory, so that upregu lation of one pathway downregulates the other. 15, 21 In other words, the autophagic and apoptotic pathways can be considered competitive determinants of cell fate. However, if the homeostatic balance between auto phagy and apoptosis is lost, either pathway can potentially drive cellular demise. Cell lines overexpressing Beclin 1, a key autophagy-regulated protein, show hyperactive autophagy and ultimately complete self-digestion. [23] [24] [25] Autophagy-associated cell death (type II programmed cell death), is characteristically caspase-independent and histologically distinct from apoptosis (type I programmed cell death), 23 so autophagy can continue to facilitate cell death even in the context of apoptotic dysfunction. 23, 26 Apoptotic dysfunction is not uncommon in cancer pathogenesis, so upregulation of autophagy, even in established tumours, can have nuanced implications in terms of cell fate. 27 In summary, the contextual meaning of autophagic activity is complex, depending not only on the presence of cancer, but on the apoptotic status as well. 22 Autophagic modulation for cancer therapy Given the dynamic role of autophagy in tumour pathogenesis, and that most cancer treatments induce autophagy, adjuvant autophagy inhibition has become an area of research interest. The results have been encouraging, and studies have shown that the pharmacological As such, growth-factor deprivation will also activate autophagy. b | The autophagosome matures by enclosure of cellular debris, consisting of organellar waste and toxic metabolites,within an isolation membrane, and is trafficked to lysosomes where it fuses and creates the autolysosome. c | The autolysosome digests cellular biomass and eliminates toxins, which provides nutrients and favourable growth conditions. Abbreviations: AKT, protein kinase B; AMPK, adenosine monophosphate-activated protein kinase; ATG13, autophagy-related protein 13; ATG101, autophagy-related protein 101; FIP200, RB1-inducible coiledcoil protein 1; PI3K, phosphoinositide 3-kinase; ULK1, serine/threonine-protein kinase ULK1.
inhibition of autophagy can enhance the cell-killing effects of cancer therapeutics in preclinical models. [28] [29] [30] On the basis of the success of preclinical reports demonstrating therapeutic efficacy, concurrent autophagy inhibition is now also being explored in a number of clinical trials for patients with refractory malignancies, including glioblastoma, breast cancer, multiple myeloma, and lung cancer. 31 Several autophagy inhibitors have been tested in both preclinical and clinical models, and these inhibitors are typically classified by the stage at which they inhibit formation of the mature autophagosome complex. Early stage inhibitors typically interfere with the recruitment of essential autophagy related proteins, whereas late stage inhibitors prevent the binding of lysosomes or the acidification of the autolysosome complex. 32 In prostate cancer research, inhibitors of autophagy used in laboratory research include 3-methyladenine, and small inhibitory RNAs (siRNAs) targeting specific autophagy-related genes (Atgs), although the use of siRNAs has largely been relegated to preclinical studies as a confirmatory tool demonstrating autophagy inhibition. More clinically applicable inhibitors of autophagy include chloroquine, its derivative hydroxychloroquine, and bafilomycin A1. 32 Chloroquine and hydroxychloroquine, which are lysosomotropic amines traditionally used to treat malaria and rheumatoid arthritis, have been most-widely studied. 10, 33 They are inexpensive and have well-known pharmacokinetic profiles, facilitating their use in clinical trials (Tables 1 and 2 ).
Other notable autophagy inhibitors being investigated in the context of prostate cancer treatment include metformin and desmethylclomipramine. Metformin, an oral biguanide that is commonly prescribed to treat non-insulin-dependent diabetes, also inhibits REVIEWS autophagy, 32 and the mechanism of this inhibition is being explored. Metformin is known to activate 5' adenosine monophosphate-activated protein kinase (AMPK), a potent inhibitor of the serine/threonine-protein kinase mTOR (mammalian target of rapamycin), 34 but this would suggest that metformin should be a stimulator of autophagy. This apparent contradiction can be explained by the proposed effect of metformin on Beclin 1, a core autophagy regulator. Results of a study published in 2010 35 showed that metformin can sequester Beclin 1, inhibiting autophagy despite the inhibition of mTOR. Metformin also has antiproliferative effects in a variety of cancer cell lines (including prostate, ovarian, breast, colorectal, and endometrial carcinoma models), [36] [37] [38] [39] [40] [41] [42] and several studies suggest that patients taking metformin for diabetes mellitus have decreased prostate cancer incidence and severity. 43, 44 Thus, metformin possesses several characteristics that make it a readily translatable autophagy inhibitor, and suggest specific efficacy in prostate cancer. Desmethylclomipramine, a tricyclic antidepressant, also inhibits autophagy. 45 Like hydroxychloroquine and metformin, its widespread use improves its value as a clinically viable autophagy inhibitor. Desmethylclomipramine is believed to decrease autophagic flux by inhibiting the fusion of the autophagosome and the lysosome, but more work is needed to fully understand its mechanism of action. 46 Although we believe that many, if not most, prostate cancer treatments induce a cytoprotective form of autophagy, several treatments, such as everolimus (RAD001), zoledronic acid, atorvastatin, YM155, and (-)-gossypol, can induce toxic, or unsustainably elevated, autophagic activity. 47 Mechanistically, these cases of cytotoxic autophagy have been attributed to the sustained activity of critical autophagy promoters, namely autophagy associated proteins and Beclin 1, 47 although 49 demon strated enhanced tumour necrosis factor α (TNF-α)-dependent apoptosis in PC3 cells (prostate cancer cells without a functioning androgen receptor) when autophagy was induced. Given the controversy currently surrounding cyotoxic autophagy, the term 'autophagy-associated cell death' is commonly used. More research is required to improve our understanding of autophagy-associated cell death and to determine whether or not there is a clinical role for a djuvant autophagy induction in prostate cancer treatment.
Prostate cancer therapies and autophagy
Androgen deprivation therapy Androgen ablation is a common therapeutic intervention for advanced prostate cancer that results in widespread death of the prostate epithelium and dramatic-albeit transient-clinical improvements. 50 Unfortunately, advanced prostate cancer treated with androgen deprivation therapy (ADT) ultimately progresses to a lethal phenotype known as castration-resistant prostate cancer (CRPC). 51 Research conducted in our laboratory and elsewhere indicates that ADT stimulates autophagic activity, facilitating the development of CRPC. 46 Androgens have an influential role in autophagy, and the androgen receptor is a key mediator. 52, 53 The androgen receptor negatively controls autophagic activity, and the targeted inhibition of this receptor positively influences autophagy (Figure 2) . 1 Bennett et al. 1 determined that treatment of LNCaP cells with bicalutamide, a non steroidal androgen receptor antagonist, induces autophagy in the absence of any additional stressors. We have further substantiated these findings, showing that targeted inhibition of the androgen receptor with enzalutamide produces significant autophagic flux in prostate cancer models in vitro and in vivo. 46 Taken together, these data suggest that ADT, and perhaps more importantly androgen receptor inhibition, can directly promote the cellular adaptations that help overcome the metabolic stress of hormone withdrawal.
Knowledge of the exact molecular events that link androgen receptor inhibition to autophagy is still somewhat fragmented, but mTOR appears to have a critical role. Xu et al. 54 demonstrated that androgen treatment directly affects mTOR activity and that the androgen receptor promotes MTOR mRNA synthesis. This finding has been reinforced by studies showing that androgen deprivation specifically decreases levels of downstream mTOR metabolites. 54 In our lab, androgen deprivation and prolonged androgen receptor blockade with enzalutamide were associated with AMPK activation and, ultimately, mTOR suppression via phospho-Raptor (regulatory-associated protein of mTOR). 46 Similarly, others have shown that AMPK directly regulates mTOR activity in response to imbalances in the core energy metabolites, AMP and ATP. 52, 55 An indirect effect of androgen receptor inhibition is hypoxia. Androgen withdrawal impedes angiogenesis, and the resultant nutrient deprivation and hypoxia further stimulate autophagy. 56 These data substantiate the influence of the androgen receptor on autophagic flux, but cannot completely explain the regulation of autophagy. For example, PC3 cell lines lacking androgen receptor can also upregulate autophagy during ADT. 52 Potential explanations for this phenomenon include alterations in proto-oncogenes like PTEN (phosphatase and tensin homologue), variations in tumour suppressors like cellular tumour antigen p53, and the aberrant expression of downstream androgen receptor targets.
Given that androgens and the androgen receptor are valuable targets in prostate cancer treatment, and that their therapeutic benefit is limited by autophagy, studies are currently underway to determine whether auto phagy modulation could improve the therapeutic effect of ADT. Available data provide evidence that concurrent androgen receptor and autophagy inhibition synergistically promote cell death, 57 and that this inhibition is dependent on both dose and duration. 51 Bennett et al. 1 demonstrated that inhibiting autophagy with 3-methyladenine enhanced cell death 1.5-fold in cells treated with bicalutamide. Colquhoun et al. 39 demonstrated that LNCaP cells treated with bicalutamide and metformin exhibited significant reductions in colony formation rates (compared with no treatment), which also held true for PC3 cell lines, albeit at much higher doses of bicalutamide and metformin. In our laboratory, clomipramine and metformin significantly increased the cytotoxicity associ ated with enzalutamide in vitro, and in mouse models in vivo, wherein enzalutamide and clomipramine in combination decreased tumour size by 91%, compared with a 78% decrease with enzalutamide and metformin. 46 Several ongoing clinical trials are evalu ating adjuvant autophagy inhibition in the context of ADT and androgen receptor blockade (Tables 1 and 2 ). In summary, the androgen receptor has important, but apparently nonessential, roles in autophagy induction. More research is needed to understand the nuanced roles that the androgen r eceptor has throughout the p rogression of prostate cancer.
Taxane-based chemotherapy
Microtubules are cytoskeletal structures that rapidly fluctuate through polymerization states to meet a multi tude of cellular needs, including mitosis, protein synthesis, and subcellular organization. 58 These processes are in high demand in rapidly dividing cells, and con sequently, targeting microtubules has been a popular strategy in cancer treatment. In prostate cancer, docetaxel (a microtubule-stabilizing agent or taxane) is a current standardof-care in men with symptomatic CRPC, providing a survival benefit of approximately 2 months. 59 Finding explanations for this limited therapeutic efficacy has been exceedingly difficult, especially with regards to autophagy. Early studies showed a variable degree of autophagic activity during taxane-based therapies, with some studies showing that taxanes induce autophagy and others showing that they inhibit autophagy. [60] [61] [62] The discrepancies in these findings can in part be explained by the fact that different concentrations of taxanes and different cell lines were used. Published in 2013, the results of a study using breast cancer cells suggest that the autophagic response to taxanes is context-dependent, with the duration of treatment, and the intensity of environmental factors contributing to the degree of a utophagic activity. 63 Despite the variability in the available data, mechanistic links between taxanes and autophagy have been described. Theoretically, taxanes should inhibit autophagy, as they target microtubules, the core constituents of autophagosome formation and trafficking, but this paradigm has limitations. Evidence shows that auto phagy can be upregulated in response to taxanes. Some researchers have proposed that taxanes only target speci fic elements of the microtubule structure, such as the mitotic spindle, leaving enough remaining function to stimulate the core events of autophagy. 64 Another explanation is that structurally damaged microtubules could induce autophagy through signalling cascades mediated by Raf-1. 65 Addded insight was provided by Notte et al., 63 who identified two key pathways, the first involving inhibition of mTOR, and the second involving activation of the c-Jun N-terminal kinase (JNK), which phosphory lates Bcl-2 and Bcl-XL and disrupts the binding of Beclin 1, freeing it to activate autophagy. 63 Interestingly, although these pathways had similar functions, they were differentially activated according to treatment duration and environmental stress. 63 Just as taxanes influence autophagy, autophagy seems to be an important factor in taxane resistance, specifically in prostate cancer cells. LNCaP-AI cells, which are chronically maintained in androgen-depleted conditions, are approximately 2.5 times more resistant to docetaxel than LNCaP cells grown in androgen-replete media. 1 Moreover, restoration of androgens to the LNCaP-AI cells can restore docetaxel sensitivity. Autophagy is believed to be responsible for this resistance, and when autophagy was suppressed with 3-methyladenine, the cytotoxic effect of bicalutamide and docetaxel increased twofold. 1 
Kinase inhibitors
Tyrosine kinases are essential mediators of signal transduction, and any aberrant activity in these kinases can result in abnormalities in cellular proliferation, differentiation, apoptosis, and metabolism. 5, 11 Src family kinases (SFKs) are a family of nonreceptor tyrosine kinases, and Src is perhaps the most widely characterized tyrosine kinase, with important roles in tumour progression in several different cancers, including glioblastoma, colon, lung, breast, and prostate cancers. 66 In prostate cancer specifically, SFK activation has been implicated in disease invasiveness and metastatic potential, specifically to bone. [67] [68] [69] SFK activity has shown oncogenic effects in both androgen-dependent and androgen-independent prostate cancers, suggesting that SFK activity is involved in the progression of prostate cancer to castration resistance. 67, 70 The pathogenesis of SFKs in prostate cancer has largely been attributed to their ability to activate the androgen receptor independent of androgen stimulation. SFK activity can be regulated by a number of growth factors during androgen deprivation (Figure 3) , including epidermal growth factor (EGF), IL-6, IL-8, and neurokines (gastrin-releasing peptide), and these factors activate important proliferative pathways, notably Ras/Raf/Erk and PI3K/Akt. 5, 67, [70] [71] [72] [73] The involvement of SFKs in prostate cancer pathogenesis, and the knowledge of prominent molecular elements of their activity, led to the introduction of SFK inhibitors, including dasatinib and saracatinib, into clinical research. Saracatinib can decrease tumour migration and metastasis in prostate cancer cell lines. 69 However, SFK inhibitors have been decidedly less success ful at inducing significant levels of apoptosis in these cell lines, possibly owing to the influence of autophagy. 70, 74 When SFKs are inhibited, the PI3K/Akt/mTOR/S6K signalling cascade is impeded, resulting in upregulation of autophagy. 5, 67, 69, 70 Additionally, SFKs are believed to regulate glucose transport (for example, by GLUT1 and GLUT4), and once glucose transport is compromised, the cells will be energetically stressed, further promoting autophagy through AMPK activation. 5, 67 Although various models directly implicate aberrant SFK activity in prostate cancer pathogenesis, and targeted inhibition of SFKs has proved somewhat useful, autophagy provides a mechanistic escape that limits the therapeutic potential of this drug class.
Inhibition of autophagy with concurrent SFK inhibition supports the idea that autophagy is associated with this limited efficacy. Inhibition of autophagy by each of three independent approaches-chloroquine, 3-methyladenine, and siRNA-directed knockdown of Atg7 (an essential autophagy constituent)-enhanced PC3 cell death by means of increased apoptotic activity. In addition, chloroquine enhanced the therapeutic efficacy of saracatinib in PC3 xenographic mouse models: after 14 days of tumour growth, the addition of chloroquine to saracatinib inhibited tumour growth by 64%, compared with 26% inhibition in tumours treated with saracatinib alone. 69 In summary, SFKs are influential components of the cellular proliferative and adaptive machinery, and their inhibition can affect prostate cancer progression. However, the therapeutic impact of SFK inhibition is limited by the paradoxical molecular overlap that supports both treatment effect and treatment resistance. Fortunately, the data seem to suggest that adjunct autophagy inhibition undermines this resistance.
Arginine deiminase
Amino acid deprivation has long been established as a cancer treatment modality. 75 A variety of amino acids, including glutamine, methionine, leucine, and arginine, have been selectively eliminated to challenge the metabolic needs of growing cancers. 75 In prostate cancer research, accumulating evidence suggests that prostate cancer cells are especially susceptible to arginine restriction. In an analysis of 88 prostate cancer specimens, none expressed argininosuccinate synthetase, suggesting limitations in de novo arginine synthesis. 75 These prostate cancers should be exquisitely sensitive to any arginine depletion, and indeed when CWR22RV1 cells (CRPC cells lacking argininosuccinate synthetase) were treated with arginine deiminase (ADI)-an enzyme that degrades arginine-cell death was accelerated. 75 These results were replicated in CWR22RV1 xenografts in nude mice. 75 When this killing effect was further analysed, AMPK was notably activated and the Akt/mTOR/ S6K pathway was found to be deactivated (Figure 4) , suggesting that not only was autophagy upregulated, but that greater therapeutic efficacy could be achieved with autophagy inhibition. Treatment of prostate cancer cell lines with chloroquine accelerated the apoptosis induced by ADI. 75 Chloroquine itself had little effect on cellular viability, supporting therapeutic synergy with ADI. The prosurvival function of auto phagy was confirmed with the siRNA knockdown of Beclin 1, which effectively inhibited autophagy and promoted apoptosis. However, the synergistic effects of ADI and autophagy inhibition were limited to CWR22RV1 cells. In LNCaP cells that express functional arginino succinate synthetase, combined ADI and chloroquine had little effect. Collectively, these data suggest that autophagy could be a valuable target in prostate cancers that are found to lack argininosuccinate synthetase. Phase I/II clinical trials in hepatoma and melanoma cell lines have already demonstrated some success with this strategy (Table 1) , but clinical trials are needed in appropriately selected patients with prostate cancer to fully determine the therapeutic efficacy of ADI with c oncurrent autophagy inhibition. 75 
Conclusions
Our understanding of prostate cancer progression continues to evolve. The dynamic role of autophagy in prostate cancer progression is a molecularly intriguing and potentially modifiable factor in prostate cancer pathogenesis. Fundamentally, the degree of autophagic activity is important: too little or too much autophagy portends either beneficial or deleterious consequences depending on the state of carcinogenesis and the involvement of therapeutic intervention. The advances in prostate cancer treatments, specifically advances in targeted androgen synthesis and androgen receptor inhibition, microtubule inhibition, cell-signalling inhibition, and amino acid deprivation, stimulate the adaptive response of autophagy in prostate cancer models. Furthermore, autophagy can be modulated in these models to improve therapeutic efficacy. To date, a number of human trials investigating autophagy in cancer have been undertaken, with several in later phases demonstrating therapeutic efficacy. Clinical trials specific to prostate cancer are ongoing, and will, we hope, further substantiate what has been observed preclinically. Moving forward, refinement of autophagy modulation is needed. Currently available autophagy modulators are relatively nonspecific, and cytotoxicity in noncancerous tissues is still a concern. 19 The influence of autophagic manipulation on immuno logical activity is also uncertain. Moreover, given the context-dependent role of autophagy, appropriate selection of patients and directional modification of auto phagy are essential.
2 Few autophagy-specific biomarkers are currently known, and the development of a greater set of biomarkers will certainly help to character ize prostate cancers that are more dependent on autophagy and to better inform treatment paradigms using autophagic modulation.
